These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38976822)

  • 1. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy.
    Spaull R; Soo AK; Batzios S; Footitt E; Whiteley R; Mink JW; Carr L; Gissen P; Kurian MA
    Neurology; 2024 Aug; 103(3):e209615. PubMed ID: 38976822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
    Lewis G; Morrill AM; Conway-Allen SL; Kim B
    J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
    Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
    Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A
    J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
    Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A
    J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
    Schulz A; Ajayi T; Specchio N; de Los Reyes E; Gissen P; Ballon D; Dyke JP; Cahan H; Slasor P; Jacoby D; Kohlschütter A;
    N Engl J Med; 2018 May; 378(20):1898-1907. PubMed ID: 29688815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
    Schulz A; Specchio N; de Los Reyes E; Gissen P; Nickel M; Trivisano M; Aylward SC; Chakrapani A; Schwering C; Wibbeler E; Westermann LM; Ballon DJ; Dyke JP; Cherukuri A; Bondade S; Slasor P; Cohen Pfeffer J
    Lancet Neurol; 2024 Jan; 23(1):60-70. PubMed ID: 38101904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.
    Hammon K; de Hart G; Vuillemenot BR; Kennedy D; Musson D; O'Neill CA; Katz ML; Henshaw JW
    Clin Transl Sci; 2021 Sep; 14(5):1810-1821. PubMed ID: 34076336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2.
    Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T
    Intern Med; 2024 Jun; 63(12):1807-1812. PubMed ID: 37926545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerliponase Alfa: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy.
    Huang WC; Ohnsman CM; Atiskova Y; Falabella P; Spitzer MS; Schulz A; Dulz S
    Invest Ophthalmol Vis Sci; 2024 Jul; 65(8):45. PubMed ID: 39078732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
    de Los Reyes E; Lehwald L; Augustine EF; Berry-Kravis E; Butler K; Cormier N; Demarest S; Lu S; Madden J; Olaya J; See S; Vierhile A; Wheless JW; Yang A; Cohen-Pfeffer J; Chu D; Leal-Pardinas F; Wang RY
    Pediatr Neurol; 2020 Sep; 110():64-70. PubMed ID: 32684372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
    Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW
    Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
    Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.
    Cherukuri A; Cahan H; de Hart G; Van Tuyl A; Slasor P; Bray L; Henshaw J; Ajayi T; Jacoby D; O'Neill CA; Schweighardt B
    Clin Immunol; 2018 Dec; 197():68-76. PubMed ID: 30205177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.